Flash Finance

Solara Active Pharma Sciences LimitedSOLARACorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Sep 2026 15 quarters of data
Consolidated Standalone
₹696.70
MCap ₹3,362 Cr · P/E 91.0
Solara Active Pharma Sciences Limited — Stock analysis & AI research Solara Active Pharma Sciences Limited — Seasonality — best & worst months Solara Active Pharma Sciences Limited — Technical indicators & charts Solara Active Pharma Sciences Limited — Technical setup — score, trend, support & resistance Solara Active Pharma Sciences Limited — Live exchange announcements
📋 Stocks With Strong Quarterly Results 📈 Bullish EMA Alignment📈 Multi-Timeframe Bullish Stocks📈 Unusual Volume Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹417 Cr
Sales · Sep 2026
+33.1% YoY
₹77 Cr
Operating Profit · Sep 2026
+121.2% YoY
18.4%
OPM % · Sep 2026
+65.8% YoY
₹28 Cr
Net Profit · Sep 2026
+381.8% YoY
₹5.92
EPS · Sep 2026
+350.8% YoY

📝 Solara Active Pharma Sciences Limited — results explained

Quarter ended September 2026 (Q2 FY27)

Solara Active Pharma Sciences Limited reported revenue of ₹417 crore for the quarter ended September 2026 (Q2 FY27), up 33.1% from ₹314 crore in the same quarter last year, and up 9.4% sequentially over the June 2026 quarter.

The company swung to a net profit of ₹28 crore from a net loss of ₹10 crore a year earlier. Earnings per share (EPS) came in at ₹5.92.

Operating profit stood at ₹77 crore — an operating margin (OPM) of 18.4%, compared with 11.1% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Solara Active Pharma Sciences Limited posted revenue of ₹1,369 crore, a growth of 6.6% over FY25, with a net loss of ₹7 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹1,535 crore with a net profit of ₹37 crore.

Valuation snapshot

At the current price of ₹696.70, SOLARA has a market capitalisation of ₹3,362 crore and a trailing P/E of about 91.0.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 18th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 41.93%, foreign institutional investors (FIIs) 11.52%, domestic institutional investors (DIIs) 3.74%, public shareholders 42.81% of Solara Active Pharma Sciences Limited.

Promoter holding slipped from 42.00% to 41.93% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹3,362 Cr
Current Price ?
₹696.7
P/E ?
90.98above ind
Industry P/E ?
37.20
P/B ?
2.34
P/S ?
2.19
P/FCF ?
33.28
Enterprise Value ?
₹3,953 Cr
EV/EBITDA ?
16.91
PEG ?
3.64
Earnings Yield ?
3.3%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹1,535 Cr
OPM ?
15.2%
Profit after tax (TTM) ?
₹37 Cr
EPS (TTM) ?
₹7.66
ROCE ?
5.0%
ROE ?
2.6%
ROA ?
1.5%
Growth
Sales — latest qtr ?
₹417 Cr
PAT — latest qtr ?
₹28 Cr
YoY qtr sales growth ?
33.1%
YoY qtr profit growth ?
381.8%
Sales growth (3y) ?
-2%
Sales growth (5y) ?
-3%
Profit growth (3y) ?
25%
Profit growth (5y) ?
N/A
Financial Health
Debt ?
₹591 Cr
Debt to Equity ?
0.41
Interest Coverage ?
0.9
Current Ratio ?
N/A
Ownership
Promoter holding ?
41.93%
Change in promoter holding ?
-0.08%
Pledged percentage ?
N/A
Market
Return 3 months ?
22.1%
Return 6 months ?
39.6%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Sep bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026 YoY % QoQ %
Sales 381352425212299363347300273319314349387382417 +33.1% +9.4%
Operating Profit 491938-1621042625845573537586277 +121.2% +24.0%
Other Income 52-4-62-120101610-7631 +10.2% -79.9%
Interest 222524253131282729242122282218 -14.6% -17.8%
Depreciation 262626262525252524242426262727 +8.8% -0.3%
Profit Before Tax 5-29-17-275-167-1388-211-10-17101628 +381.8% +74.5%
Net Profit 4-19-17-275-255-1388-211-10-17101628 +381.8% +74.5%
EPS 0.79-4.07-3.58-57.36-53.20-3.742.222.24-0.582.46-2.36-4.822.653.525.92 +350.8% +68.2%
OPM % 12.8% 5.4% 8.8% -76.3% 3.3% 11.5% 17.8% 19.2% 16.6% 17.9% 11.1% 10.7% 14.9% 16.2% 18.4% +65.8% +13.6%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹1,284 Cr ₹1,369 Cr ₹1,535 Cr +6.6%
Operating Profit ₹207 Cr ₹187 Cr ₹234 Cr -9.6%
OPM % 16.09% 13.64% 15.23% -15.2%
NPM % 0.04% -0.54% 2.41% -1450.0%
Other Income ₹8 Cr ₹0 Cr ₹2 Cr -96.8%
Depreciation ₹99 Cr ₹100 Cr ₹105 Cr +0.5%
Interest ₹115 Cr ₹95 Cr ₹89 Cr -17.5%
EBIT ₹107 Cr ₹87 Cr ₹129 Cr -18.9%
PBT ₹1 Cr ₹-7 Cr ₹37 Cr -1496.2%
Tax — — — —
Net Profit ₹1 Cr ₹-7 Cr ₹37 Cr -1470.4%
EPS ₹0.14 ₹-2.07 ₹7.27 -1578.6%
Material Cost — ₹315 Cr ₹402 Cr —
Employee Cost — ₹108 Cr ₹114 Cr —
Extraordinary Items ₹0 Cr ₹-7 Cr ₹-11 Cr —

🏛️ Balance Sheet (latest 5 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026 % Chg
Equity Capital 3636404548 +7.0%
Reserves 1,4648981,0541,2081,388 +14.9%
Borrowings 1,0131,012796687591 -13.9%
Other Liabilities 386406342393427 +8.6%
Total Liabilities 2,8992,3512,2322,3332,454 +5.2%
Fixed Assets 1,3641,2681,1931,2381,201 -3.0%
CWIP 238256280205208 +1.3%
Investments 22253 -48.8%
Other Assets 1,2958257578861,043 +17.7%
Total Assets 2,8992,3512,2322,3332,454 +5.2%

📦 Working Capital (latest 1 periods)

Metric Sep 2026 % Chg
Inventories 367 —
Trade Receivables 506 —
Trade Payables 319 —

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 156109213153 -28.2%
Cash from Investing Activity -81-4-37-99 -167.6%
Cash from Financing Activity -113-106-180-54 +70.0%
Net Cash Flow -38-0-41 +125.0%
Free Cash Flow 4669173101 -41.6%
CFO/OP 106%-113%104%83% -20.2%

💧 Half-year Cash Flow (latest 1 periods)

Metric Sep 2026 % Chg
Cash from Operating Activity 63 —
Cash from Investing Activity -48 —
Cash from Financing Activity 5 —
Net Cash Flow 20 —

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 1369993117 +25.8%
Inventory Days 258163185170 -8.1%
Days Payable 142142145146 +0.7%
Cash Conversion Cycle 252120133140 +5.3%
Working Capital Days 20-128-62-23 +62.9%
ROCE % 2%-9%6%5% -16.7%

👥 Shareholding (latest 5 periods)

Metric Sep 2025Dec 2025Mar 2026May 2026Jun 2026 % Chg
Promoters 42.01%42.00%42.00%42.00%41.93% -0.2%
FIIs 13.58%11.98%11.59%11.34%11.52% +1.6%
DIIs 2.69%3.64%3.75%3.77%3.74% -0.8%
Public 41.71%42.37%42.66%42.89%42.81% -0.2%
No. of Shareholders 72,47971,89070,40070,03770,490 +0.6%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 KOPRAN Kopran ₹281.55 1,361 54.5 700 25 8.7% 3.6% -96.0% -97.6% 13.9% -10.0%
❓ Frequently asked questions
What was Solara Active Pharma Sciences Limited's revenue in Q2 FY27?
Solara Active Pharma Sciences Limited reported revenue of ₹417 crore for the quarter ended September 2026 (Q2 FY27), up 33.1% from ₹314 crore in the same quarter last year, and up 9.4% sequentially over the June 2026 quarter.
What was Solara Active Pharma Sciences Limited's net profit in Q2 FY27?
The company swung to a net profit of ₹28 crore from a net loss of ₹10 crore a year earlier. Earnings per share (EPS) came in at ₹5.92.
What is SOLARA's market capitalisation and P/E ratio?
At the current price of ₹696.70, SOLARA has a market capitalisation of ₹3,362 crore and a trailing P/E of about 91.0.
Who owns Solara Active Pharma Sciences Limited? (shareholding pattern)
As of Jun 2026, promoters held 41.93%, foreign institutional investors (FIIs) 11.52%, domestic institutional investors (DIIs) 3.74%, public shareholders 42.81% of Solara Active Pharma Sciences Limited.
TTM ends 2026-09-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI